Humira (Adalimumab)
Launch:
Humira was launched by AbbVie (formerly part of Abbott Laboratories) in 2002.
Manufacturer:
AbbVie
Global Sales in 2023:
Humira generated approximately $20 billion in global sales in 2023, maintaining its status as one of the best-selling drugs globally.
Why It’s the Best:
Humira is a TNF inhibitor, used to treat a variety of autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Its effectiveness in managing chronic inflammation has made it a cornerstone therapy for millions of patients worldwide. Despite the introduction of biosimilars, Humira continues to dominate due to its established efficacy and AbbVie’s strategic management of its market exclusivity.